Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3084% below fair value
$3.01−0.23 (-7.10%)
Close on Nov 13, 2026Market cap $51.62MP/E –Yield –
Tonix Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Tonix Pharmaceuticals's enterprise value was -$111.25M on Nov 11, 2026, against -$28.96M a year earlier. Over the last 5 years it ranged from -$111.25M to $29.15B, with a median of $115.75M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$111.25M | – |
| 2025 | Dec 31, 2025 | -$32.52M | -204.6% |
| 2024 | Dec 31, 2024 | $31.09M | -86.0% |
| 2023 | Dec 29, 2023 | $222.15M | -94.5% |
| 2022 | Dec 30, 2022 | $4.02B | -86.2% |
| 2021 | Dec 31, 2021 | $29.15B | +52.1% |
| 2020 | Dec 31, 2020 | $19.17B | +5161.4% |
| 2019 | Dec 31, 2019 | $364.28M | -92.2% |
| 2018 | Dec 31, 2018 | $4.67B | -91.2% |
| 2017 | Dec 29, 2017 | $53.18B | +90.2% |
| 2016 | Dec 30, 2016 | $27.96B | -90.5% |
| 2015 | Dec 31, 2015 | $294.47B | +131.8% |
| 2014 | Dec 31, 2014 | $127.03B | +28.4% |
| 2013 | Dec 31, 2013 | $98.97B | +181.2% |
| 2012 | Dec 31, 2012 | $35.20B | – |
See a number that looks wrong?